Journal of Clinical Endocrinology & Metabolism, Vol 77, 963-968, Copyright © 1993 by Endocrine Society

ARTICLES

Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors

E Hershkovitz, M Marbach, E Bosin, J Levy, CT Roberts Jr, D LeRoith, AV Schally and Y Sharoni
Clinical Biochemistry Department, Faculty of Health Sciences, Ben- Gurion University of the Negev, Soroka Medical Center of Kupat Holim, Beer-Sheva, Israel.

Several studies have supported the idea that LH-releasing hormone (LHRH) antagonists have a direct effect on mammary tumor cells. In this study, we have evaluated the potential role of the insulin-like growth factors (IGFs) on the growth of MCF-7 mammary tumor cells and the effect of LHRH analogs on IGF action. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3 times more potent than IGF-II and 30 times more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. IGFs released by MCF-7 cells were measured by specific RIA after acid extraction and chromatography, so as to avoid the interference of IGF-binding proteins. MCF-7 cells secreted IGF-II, but not IGF-I. Estradiol (10(-9) mol/L) stimulated IGF-II release; this release preceded the effect of estradiol on cell growth. The LHRH antagonist [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit6,D-Ala10] LHR H (SB-75, CETRORELIX) inhibited basal, estrogen-induced, and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from MCF-7 cells. This effect preceded the inhibition of tumor cell growth. We conclude that a LHRH antagonist can inhibit the growth of breast tumors by interfering with the autocrine action of IGF-II and by directly inhibiting the growth stimulatory effect of IGFs.

This article has been cited by other articles:

				D. Haouzi, S. Assou, K. Mahmoud, S. Tondeur, T. Reme, B. Hedon, J. De Vos, and S. Hamamah Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients Hum. Reprod., June 1, 2009; 24(6): 1436 - 1445. [Abstract] [Full Text] [PDF]

				A. R Gunthert, C. Grundker, A. Olota, J. Lasche, N. Eicke, and G. Emons Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen Eur. J. Endocrinol., October 1, 2005; 153(4): 613 - 625. [Abstract] [Full Text] [PDF]

				K. Kawamura, J. Fukuda, J. Kumagai, Y. Shimizu, H. Kodama, A. Nakamura, and T. Tanaka Gonadotropin-Releasing Hormone I Analog Acts as an Antiapoptotic Factor in Mouse Blastocysts Endocrinology, September 1, 2005; 146(9): 4105 - 4116. [Abstract] [Full Text] [PDF]

				A. Chen, E. Kaganovsky, S. Rahimipour, N. Ben-Aroya, E. Okon, and Y. Koch Two Forms of Gonadotropin-releasing Hormone (GnRH) Are Expressed in Human Breast Tissue and Overexpressed in Breast Cancer: A Putative Mechanism for the Antiproliferative Effect of GnRH by Down-Regulation of Acidic Ribosomal Phosphoproteins P1 and P2 Cancer Res., February 1, 2002; 62(4): 1036 - 1044. [Abstract] [Full Text] [PDF]

				N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]

				E. R. Hernandez Embryo implantation and GnRH antagonists: Embryo implantation: the Rubicon for GnRH antagonists Hum. Reprod., June 1, 2000; 15(6): 1211 - 1216. [Abstract] [Full Text] [PDF]

				S. K. Kang, K.-C. Choi, K. W. Cheng, P. S. Nathwani, N. Auersperg, and P. C. K. Leung Role of Gonadotropin-Releasing Hormone as an Autocrine Growth Factor in Human Ovarian Surface Epithelium Endocrinology, January 1, 2000; 141(1): 72 - 80. [Abstract] [Full Text] [PDF]

				V. J. Csernus, A. V. Schally, H. Kiaris, and P. Armatis Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro PNAS, March 16, 1999; 96(6): 3098 - 3103. [Abstract] [Full Text] [PDF]

				M. Montagnani Marelli, R. M. Moretti, D. Dondi, M. Motta, and P. Limonta Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells Endocrinology, January 1, 1999; 140(1): 329 - 334. [Abstract] [Full Text]

				J.A. Clapper, J.L. Snyder, A.J. Roberts, D.L. Hamernik, and G.E. Moss Estradiol Increases Relative Amounts of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 in Serum and Expression of IGFBP-2 in Anterior Pituitaries of Ewes Biol Reprod, July 1, 1998; 59(1): 124 - 130. [Abstract] [Full Text]

				R. J. Urban and Y. Bodenburg Transcriptional Activation of the Porcine P450 11A Insulin-like Growth Factor Response Element in MCF-7 Breast Cancer Cells J. Biol. Chem., December 6, 1996; 271(49): 31695 - 31698. [Abstract] [Full Text] [PDF]